News coverage about Teladoc (NYSE:TDOC) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teladoc earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the health services provider an impact score of 46.7593699502762 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media headlines that may have impacted Accern’s analysis:

Several equities analysts recently commented on TDOC shares. Zacks Investment Research raised shares of Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. Cantor Fitzgerald reaffirmed a “hold” rating and set a $31.00 target price on shares of Teladoc in a report on Tuesday, September 26th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $42.00 target price on shares of Teladoc in a report on Friday, September 29th. Cowen reaffirmed an “outperform” rating and set a $39.00 target price on shares of Teladoc in a report on Saturday, September 30th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $40.00 target price on shares of Teladoc in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $39.31.

Shares of Teladoc (NYSE TDOC) opened at $32.75 on Wednesday. The stock has a market cap of $1,980.00 and a price-to-earnings ratio of -22.59. Teladoc has a twelve month low of $15.65 and a twelve month high of $38.40. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 5.08.

Teladoc (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). The firm had revenue of $68.70 million during the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. Teladoc’s revenue was up 112.0% on a year-over-year basis. During the same period last year, the business earned ($0.33) EPS. equities analysts expect that Teladoc will post -1.58 earnings per share for the current year.

In other Teladoc news, CFO Mark Hirschhorn sold 30,000 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $32.99, for a total value of $989,700.00. Following the sale, the chief financial officer now owns 5,203 shares of the company’s stock, valued at approximately $171,646.97. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the sale, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at $23,695,430.39. The disclosure for this sale can be found here. In the last three months, insiders sold 150,000 shares of company stock worth $4,930,700. Insiders own 4.47% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Teladoc (TDOC) Share Price” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/17/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-teladoc-tdoc-share-price.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.